lamivudine has been researched along with Adverse Drug Event in 36 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (16.67) | 29.6817 |
2010's | 26 (72.22) | 24.3611 |
2020's | 4 (11.11) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Buzón, L; De la Fuente, S; De Los Santos, I; Dueñas-Gutiérrez, C; Ferreira, E; Gómez, J; Iribarren, JA; Moran, MA; Moreno, E; Pedrero-Tomé, R; Pousada, G; Troya, J | 1 |
Chiarabini, T; Devred, I; Kayembe, K; Lacombe, K; Lambert-Niclot, S; Meyohas, MC; Rougier, H; Shinga, BW; Valin, N | 1 |
Badowski, ME; Brizzi, MB; Chiampas, TD; Michienzi, SM; Patel, MC; Young, JD | 1 |
Dollfus, C; Lemoine, A; Michot, J; Tounian, P; Viala, J | 1 |
Aweeka, F; Bradford, S; Browning, R; Coletti, A; Costello, D; Graham, B; Hughes, E; Kamthunzi, P; Kawalazira, R; Mmbaga, BT; Moye, J; Musoke, P; Nathoo, K; Norman, J; Owor, M; Purdue, L; Reding, C; Tierney, C; Whalen, ME; Wiesner, L; Ziemba, L | 1 |
Bonolo, PF; Ceccato, MDGB; Costa, JO; Dos Santos, H; Mendes, JC; Reis, AMM; Silveira, MR | 1 |
Chen, TC; Chuang, ZM | 1 |
Andreatta, K; Brar, I; Brinson, C; Cheng, A; Custodio, J; Liu, H; López-Cortés, L; Martin, H; Mills, A; Molina, JM; Podzamczer, D; Quirk, E; Ruane, P; Stellbrink, HJ; Ward, D | 1 |
Adeyeye, CM; Ali, I; Aliu, R; Awodele, O; Oni, Y | 1 |
Anugulruengkitt, S; Chokephaibulkit, K; Cressey, TR; Jantarabenjakul, W; Ounchanum, P; Pancharoen, C; Punnahitanon, S; Puthanakit, T; Sophonphan, J; Srirompotong, U; Suntarattiwong, P | 1 |
Lungu, M; Mathews, T; Tapsfield, J; van Oosterhout, JJ | 1 |
Bao, W; Chan, HL; Gane, EJ; Hou, J; Jia, J; Liaw, YF; Naoumov, NV; Niu, J; Papatheodoridis, G; Thongsawat, S; Trylesinski, A; Wan, M; Wang, Y | 1 |
An, JH; Jang, HC; Jang, MO; Jung, SI; Kang, SJ; Kim, J; Kim, SE; Park, KH | 1 |
Bentaleb, H; Cisse, VM; Dia Badiane, NM; Dieng, AB; Diop, BM; Diop, SA; Diouf, A; Fortes Déguénonvo, L; Ka, D; Lakhe, NA; Leye, MM; Manga, MN; Ndour, CT; Seydi, M; Soumaré, M; Sow, PS | 1 |
Bock, CT; Brosteanu, O; Fiedler, GM; Franke, A; Manns, MP; Römmele, U; Rößler, S; Ruf, B; Spengler, U; Teuber, G; Thiery, J; Tillmann, HL; Trautwein, C; Wächtler, M; Wedemeyer, H; Wiegand, J; Zeuzem, S | 1 |
Dziuban, EJ; Koumans, EH; Raizes, E | 1 |
Angarano, G; Bellacosa, C; Coladonato, L; Fasano, M; Grattagliano, V; Lapadula, G; Leone, A; Maggi, P; Montinaro, V; Santantonio, T; Volpe, A | 1 |
Aurpibul, L; Chokephaibulkit, K; Cressey, TR; Phongsamart, W; Sirisanthana, V; Sricharoenchai, S; Sudjaritruk, T; Wittawatmongkol, O | 1 |
Inui, A; Isonuma, H; Naito, T; Saita, M; Suzuki, A; Uehara, Y | 1 |
Cook, A; Gibb, DM; Kasirye, P; Mhute, T; Mugarura, L; Munjoma, M; Musiime, V; Nahirya-Ntege, P; Naidoo-James, B; Nankya, I; Ndashimye, E; Snowden, W; Spyer, MJ; Thomason, MJ; Thoofer, NK; Walker, AS | 1 |
Li, YH; Wu, HM; Xu, Y; Yang, J; Yang, JH; Yang, LH; Yue-Meng, W | 1 |
Barnett, BS; Chaweza, T; Hosseinipour, MC; Ngambi, W; Phiri, S; Tweya, H | 1 |
D'Andrea, M; Dessanti, ML; Miglioresi, L; Morrone, A; Nosotti, L; Paviglianiti, A; Petti, MC; Pimpinelli, F | 1 |
Cao, J; Chen, EQ; Lei, BJ; Liu, L; Tang, H; Wang, JR; Wang, LC | 1 |
Amin, J; Baker, D; Bloch, M; Carr, A; Cooper, DA; Emery, S; Martin, A | 1 |
Reiss, P | 1 |
Aurpibul, L; Capparelli, E; Chokephaibulkit, K; Cressey, TR; Eksaengsri, A; Hongsiriwon, S; Kabat, B; Limwongse, C; McIntosh, K; Muresan, P; Ngampiyaskul, C; Sirisanthana, V; Smith, ME; Toye, M; Wittawatmongkol, O; Yogev, R | 1 |
Agu, KA; Akpoigbe, KJ; Badru, T; Chabikuli, O; Eluwa, GI; Hamelmann, C | 1 |
Akbal, E; Akin, E; Alkan, E; Ataseven, H; Aygün, C; Başar, O; Baykal, O; Coban, S; Demir, M; Gülşen, MT; Ibiş, M; Koçkar, MC; Köklü, S; Köksal, AŞ; Küçükazman, M; Nadir, I; Ozdil, K; Pürnak, T; Tuna, Y; Yildirim, B; Yüksel, I; Yüksel, O | 1 |
Chersich, M; Fairlie, L; Kuhn, L; Meyers, T; Moultrie, H; Palmer, M | 1 |
Haché, C; Villeneuve, JP | 1 |
Samuels, DC | 1 |
2 review(s) available for lamivudine and Adverse Drug Event
Article | Year |
---|---|
Lamivudine treatment in patients with chronic hepatitis B and cirrhosis.
Topics: Disease Progression; Drug-Related Side Effects and Adverse Reactions; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis | 2006 |
Computational models of antiviral toxicity.
Topics: Anti-HIV Agents; Computer Simulation; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Lamivudine; Molecular Structure; Stavudine; Zidovudine | 2007 |
7 trial(s) available for lamivudine and Adverse Drug Event
Article | Year |
---|---|
Pharmacokinetics and Safety of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in HIV-infected Children With Severe Acute Malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092.
Topics: Africa South of the Sahara; Anti-HIV Agents; Area Under Curve; Child, Preschool; Chromatography, Liquid; Cohort Studies; Drug Combinations; Drug Elimination Routes; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Infant; Lamivudine; Lopinavir; Male; Patient Safety; Ritonavir; Severe Acute Malnutrition; Tandem Mass Spectrometry; Zidovudine | 2021 |
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phas
Topics: Adult; Aged; Amides; Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Substitution; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Sustained Virologic Response; Tenofovir; Viral Load; Young Adult | 2018 |
Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Telbivudine; Thymidine; Treatment Outcome | 2013 |
Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Bilirubin; DNA, Viral; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Lamivudine; Middle Aged; Placebos; Prospective Studies; Treatment Outcome | 2014 |
Once vs twice-daily abacavir and lamivudine in African children.
Topics: Adolescent; Africa; Anti-HIV Agents; Child; Child, Preschool; Dideoxynucleosides; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Immune Reconstitution; Infant; Lamivudine; Male; Medication Adherence; Sustained Virologic Response; Treatment Outcome | 2016 |
Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; HIV Infections; HLA-B Antigens; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.
Topics: Anti-HIV Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biological Availability; Body Weight; Child; Child, Preschool; Cytochrome P-450 CYP2B6; Drug Administration Schedule; Drug Combinations; Drug Dosage Calculations; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; HIV; HIV Infections; Humans; Infant; Lamivudine; Male; Nevirapine; Oxidoreductases, N-Demethylating; Reverse Transcriptase Inhibitors; Tablets; Zidovudine | 2011 |
27 other study(ies) available for lamivudine and Adverse Drug Event
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV.
Topics: Anti-HIV Agents; Drug-Related Side Effects and Adverse Reactions; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Retrospective Studies; Rilpivirine | 2023 |
Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV.
Topics: Adult; Anti-HIV Agents; Cobicistat; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Fumarates; HIV Infections; Humans; Lamivudine; Tenofovir | 2023 |
Real-world evaluation of the safety and tolerability of abacavir/dolutegravir/lamivudine in an incarcerated population.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Illinois; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prisoners; Prisons; Pyridones; Retrospective Studies; Treatment Outcome | 2019 |
Antiretroviral Prophylaxis: A Digestive Complication to Know.
Topics: Anti-HIV Agents; Child; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Lamivudine; Zidovudine | 2021 |
Adverse reactions associated with first-line regimens in patient initiating antiretroviral therapy.
Topics: Adolescent; Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Brazil; Cross-Sectional Studies; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones; Quality of Life; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2018 |
Photoallergic dermatitis associated with fixed-dose combination of antiretroviral agent (abacavir-lamivudine-dolutegravir).
Topics: Adult; Anti-Retroviral Agents; Dermatitis, Photoallergic; Dideoxynucleosides; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Heterocyclic Compounds, 3-Ring; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Skin | 2018 |
Patterns of adverse drug reaction signals in NAFDAC pharmacovigilance activities from January to June 2015: safety of drug use in Nigeria.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; Anti-HIV Agents; Child; Child, Preschool; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Middle Aged; Nevirapine; Nigeria; Pharmacovigilance; Sex Factors; Young Adult; Zidovudine | 2018 |
Safety of 6-week Neonatal Triple-combination Antiretroviral Postexposure Prophylaxis in High-risk HIV-exposed Infants.
Topics: Anti-Retroviral Agents; Chemoprevention; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Male; Nevirapine; Post-Exposure Prophylaxis; Prospective Studies; Thailand; Treatment Outcome; Zidovudine | 2019 |
Underreporting of side effects of standard first-line ART in the routine setting in Blantyre, Malawi.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Ambulatory Care Facilities; Anti-HIV Agents; Cross-Sectional Studies; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Interviews as Topic; Lamivudine; Lipodystrophy; Malawi; Male; Middle Aged; Nevirapine; Peripheral Nervous System Diseases; Prevalence; Stavudine; Surveys and Questionnaires; Urban Population | 2011 |
Clinical experience of raltegravir with abacavir/lamivudine or zidovudine/lamivudine in HIV-infected Korean adults.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Male; Middle Aged; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; Republic of Korea; Retrospective Studies; Treatment Outcome; Viral Load; Young Adult; Zidovudine | 2013 |
[Evaluation of tolerance of zidovudine-lamivudine-nevirapine combination in HIV 1 patients in Fann Teaching Hospital in Dakar].
Topics: Adult; Anti-HIV Agents; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Hospitals, Teaching; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Retrospective Studies; Senegal; Zidovudine | 2013 |
A farewell to didanosine: harm reduction and cost savings by eliminating use of didanosine.
Topics: Cost Savings; Didanosine; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Harm Reduction; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Treatment Outcome | 2015 |
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study.
Topics: Adenine; Adult; Aged; Antiviral Agents; Bone Diseases; Drug-Related Side Effects and Adverse Reactions; Female; Glomerular Filtration Rate; Hematuria; Hepatitis B, Chronic; Humans; Hypophosphatemia; Kidney Diseases; Lamivudine; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Proteinuria; Vitamin D Deficiency | 2015 |
Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Bone Density; Calcium; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Prospective Studies; RNA, Viral; Tenofovir; Treatment Outcome; Urinalysis; Viral Load | 2015 |
Raltegravir and Abacavir/Lamivudine in Japanese Treatment-Naïve and Treatment-Experienced Patients with HIV Infection: a 48-Week Retrospective Pilot Analysis.
Topics: Adult; Anti-HIV Agents; Asian People; Dideoxynucleosides; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Hyperlipidemias; Kidney Function Tests; Lamivudine; Lipids; Liver Function Tests; Male; Middle Aged; Nausea; Pilot Projects; Raltegravir Potassium; Retrospective Studies; Treatment Outcome; Viral Load; Young Adult | 2016 |
Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug-Related Side Effects and Adverse Reactions; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Retrospective Studies; Seroconversion; Telbivudine; Thymidine; Treatment Outcome; Viral Load | 2017 |
Assessment of non-standard HIV antiretroviral therapy regimens at Lighthouse Trust in Lilongwe, Malawi.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Lamivudine; Malawi; Male; Nevirapine; Stavudine; Treatment Outcome; Trust; Young Adult | 2016 |
The controversial role of lamivudine prophylaxis in occult HBV carriers treated with chemo-immune therapy.
Topics: Antiviral Agents; Carrier State; Chemoprevention; Drug-Related Side Effects and Adverse Reactions; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Humans; Lamivudine; Lymphoma; Retrospective Studies | 2009 |
Combination of Lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Enzymes; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Male; Organophosphonates; Treatment Outcome; Viral Load; Young Adult | 2010 |
The art of managing human immunodeficiency virus infection: a balancing act.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Tenofovir; Treatment Outcome | 2009 |
Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Exanthema; Female; HIV Infections; Humans; Incidence; Lamivudine; Male; Middle Aged; Nevirapine; Nigeria; Organophosphonates; Pain; Retrospective Studies; Risk Factors; Stavudine; Tenofovir; Zidovudine | 2012 |
Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Blood Chemical Analysis; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Turkey | 2013 |
Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Retrospective Studies; Risk Factors; South Africa; Stavudine; Time Factors | 2013 |